D.R. AKBEROVA¹, A.KH. ODINTSОVA², D.I. ABDULGANIEVA^{1, 2}

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

  Contact details:

Akberova D.R. — PhD (medicine), Assistant Lecturer of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 237-32-61, e-mail: dile4ek@mail.ru

We evaluated intestinal permeability by triple sugar test in patients with autoimmune liver diseases. Patients were divided into groups with autoimmune hepatitis, primary biliary cholangitis and overlap syndrome (autoimmune hepatitis/primary biliary cholangitis). 102 people were included in the cross-sectional study: 72 patients with autoimmune liver diseases and 30 healthy volunteers. Diagnose based on recommendations — EASL (2017), AASLD (2019), IAIHG (2021). Small intestine permeability was evaluated by the ratio of lactulose/mannitol in urine, large bowel permeability by the level of sucralose in urine (nmol/l). We used the method of high-performance liquid chromatography–mass spectrometry. Patients with autoimmune liver diseases had increased small intestine permeability – 0.12 [0.07; 0.234] (p < 0.001) compared to the control group — 0.013 [0.01; 0.025]. Large bowel permeability — 760.8 [386.4; 1640] nmol/l did not differ from group control — 785.6 [408; 1027.2]. Increased small intestine permeabilityin patients with autoimmune liver diseases: stage of hepatitis — 0.17 [0.118; 0.253] (p < 0.001), liver cirrhosis — 0.106 [0.07; 0.23] (p < 0.001) compared with the control group. Large bowel permeability in patients with hepatitis and in liver cirrhosis did not differ from control group. Increased values of the triple sugar test were detected in patients with autoimmune hepatitis (increased permeability of the small intestine (0,09 [0,07; 0,17] (p < 0.05), increased permeability of large bowel — 1091,2 [760; 2352] (p < 0.05)) and overlap syndrome (increased small intestine permeability — 0.18 [0,086; 0,3] (p < 0,05) and increased large bowel permeability — 880 [424; 1680] (p < 0,05)) at the stage of liver cirrhosis.

Patients with autoimmune liver diseases show the increased permeability of the small intestine. The presence of increased permeability of the small and large intestine may indicate the progression of the disease.

Key words: autoimmune liver diseases, intestinal permeability, autoimmune hepatitis, overlap syndrome, primary biliary cholangitis.

REFERENCES

1. Casas O.Y., Ramírez G.S., Zuluaga J.I. Síndrome de superposición: hepatitis autoinmune y colangitisbiliarprimaria. Resultados a largo plazo de una cohorteretrospectivaen un hospital universitario. Gastroenterología y Hepatología, 2018, vol. 41 (9), pp. 544–552.
2. Galaski J., Weiler-Normann C., Schakat M. et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. Journal of Hepatology, 2021, vol. 74 (2), pp. 312–320.
3. Lemoinne S., Heurgue A., Bouzbib C. et al. Non-invasive diagnosis and follow-up of autoimmune hepatitis. Clinics and Research in Hepatology and Gastroenterology, 2022, vol. 46 (1), p. 101772.
4. Pape S., Schramm C., Gevers T.J.G. Clinical management of autoimmune hepatitis. United European gastroenterology journal, 2019, vol. 7 (9), pp. 1156–1163.
5. Nguyen H.H., Shaheen A.A., Baeza N. et al. Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS One, 2018, vol. 13 (3), p. e0193960.
6. Fan X., Zhu Y., Men R. et al. Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology, 2018, vol., 2018.
7. Liu C., Wang Y.L., Yang Y.Y. et al. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. The FASEB Journal, 2021, vol. 35 (10), pp. e21871.
8. Odenwald M.A., Turner J.R. The intestinal epithelial barrier: a therapeutic target? Nature reviews Gastroenterology & hepatology, 2017, vol. 14 (1), pp. 9–21.
9. Tripathi A., Debelius J., Brenner D.A. et al. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nature reviews. Gastroenterology & hepatology, 2018, vol. 15 (7), pp. 397–411.
10. Wang R., Tang R., Li B. et al. Gut microbiome, liver immunology, and liver diseases. Cellular & molecular immunology, 2021, vol. 18 (1), pp. 4–17.
11. Abdollahi M.R., Somi M.H., Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. World journal of gastroenterology: WJG, 2013, vol. 19 (23), p. 3629.
12. Czaja A.J. Autoimmune hepatitis. Part A: pathogenesis. Expert review of gastroenterology & hepatology, 2007, vol. 1 (1), pp. 113–128.
13. Lin R., Zhou L., Zhang J., Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. International journal of clinical and experimental pathology, 2015, vol. 8 (5), p. 5153.
14. Dastych M., Novotná H., Číhalová J. Lactulose / mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn’s disease. Digestive diseases and sciences, 2008, vol. 53, pp. 2789–2792.
15. Volk M.L., Reau N. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient‐Friendly Summary of the 2019 AASLD Guidelines. Clinical Liver Disease, 2021, vol. 17 (2), p. 85.
16. European Association for the Study of the Liver. Electronic address: [email protected]. European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J. Hepatol, 2017, vol. 67, pp. 145–172.
17. Galaski J., Weiler-Normann C., Schakat M. et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. Journal of Hepatology, 2021, vol. 74 (2), pp. 312–320.
18. Benjamin J., Singla I.A. et al. Intestinal permeability and complications in liver cirrhosis: A prospective cohort study. Hepatology Research, 2013, vol. 43 (2), pp. 200–207.
19. Norman K., Pirlich M., Schulzke J.D. et al. Increased intestinal permeability in malnourished patients with liver cirrhosis. European journal of clinical nutrition, 2012, vol. 66 (10), pp. 1116–1119.
20. Pijls K.E., Koek G.H., Elamin E.E. et al. Large intestine permeability is increased in patients with compensated liver cirrhosis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2014, vol. 306 (2), pp. G147–G153.
21. Tsiaoussis G.I., Assimakopoulos S.F., Tsamandas A.C. et al. Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World journal of hepatology, 2015, vol. 7 (17), p. 2058.
22. Feld J.J. Abnormal intestinal permeability in primary biliary cirrhosis. Digestive diseases and sciences, vol. 51, pp. 1607–1613.